The Experts below are selected from a list of 63579 Experts worldwide ranked by ideXlab platform
Simona Gabriele - One of the best experts on this subject based on the ideXlab platform.
-
livrelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs a 6 week single arm pilot study
PLOS ONE, 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BACKGROUND Chronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins. METHODS An open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate. RESULTS A total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were <0.0001 and 0.0003 for the left and right leg, respectively. CONCLUSION It is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study. TRIAL REGISTRATION Clinicaltrial.gov: NCT03653793.
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study
2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world’s population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study.
'Public Library of Science (PLoS)', 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were ConclusionIt is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study.Trial registrationClinicaltrial.gov: NCT03653793
Heather C. Dwyer - One of the best experts on this subject based on the ideXlab platform.
-
livrelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs a 6 week single arm pilot study
PLOS ONE, 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BACKGROUND Chronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins. METHODS An open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate. RESULTS A total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were <0.0001 and 0.0003 for the left and right leg, respectively. CONCLUSION It is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study. TRIAL REGISTRATION Clinicaltrial.gov: NCT03653793.
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study
2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world’s population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study.
'Public Library of Science (PLoS)', 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were ConclusionIt is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study.Trial registrationClinicaltrial.gov: NCT03653793
Perry V. Mayer - One of the best experts on this subject based on the ideXlab platform.
-
livrelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs a 6 week single arm pilot study
PLOS ONE, 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BACKGROUND Chronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins. METHODS An open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate. RESULTS A total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were <0.0001 and 0.0003 for the left and right leg, respectively. CONCLUSION It is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study. TRIAL REGISTRATION Clinicaltrial.gov: NCT03653793.
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study
2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world’s population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study.
'Public Library of Science (PLoS)', 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were ConclusionIt is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study.Trial registrationClinicaltrial.gov: NCT03653793
David C. Baranowski - One of the best experts on this subject based on the ideXlab platform.
-
livrelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs a 6 week single arm pilot study
PLOS ONE, 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BACKGROUND Chronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins. METHODS An open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate. RESULTS A total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were <0.0001 and 0.0003 for the left and right leg, respectively. CONCLUSION It is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study. TRIAL REGISTRATION Clinicaltrial.gov: NCT03653793.
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study
2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world’s population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were
-
LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study.
'Public Library of Science (PLoS)', 2018Co-Authors: Heather C. Dwyer, David C. Baranowski, Perry V. Mayer, Simona GabrieleAbstract:BackgroundChronic Venous Disease is characterized by morphological abnormalities of the venous system. Affected limbs are classified in increasing clinical severity with the Clinical Etiological Anatomical and Pathological system from C0 to C6. Limbs assessed at C3 through C6 meet the criteria of Chronic Venous Insufficiency. Chronic Venous Insufficiency of the Lower Limbs is a very common pathology affecting approximately ~40% of the world's population. This study observes the use of the LivRelief Varicose Vein Cream, a Natural Health Product that is licensed for sale by Health Canada, for use in the treatment of varicose veins.MethodsAn open label, single arm interventional, pilot study was conducted to determine the feasibility of recruitment and Data collection in this population. To accomplish this, the cream was provided to all enrolled subjects. Subsequently, objective and subjective measures were performed at baseline and after 6 weeks of at-home use. Recruitment and Data collection targets of at least 70% were established and the Data collected at both timepoints were compared and analyzed using a paired t-test. Results were also reported as proportions where appropriate.ResultsA total of 32 subjects were enrolled. The pre-defined feasibility objectives for recruitment and Data collection were met with the enrolment of 97% of all screened patients and the collection of 94% of all Scheduled Data. The most significant therapeutic improvement was seen in the results of the Venous Clinical Severity Score where 66% of the treated legs experienced a decrease in severity after 6 weeks of treatment. P values were ConclusionIt is feasible to recruit and collect Data with the chosen outcome assessments within this population. Preliminary results suggest that the product could improve some of the clinical symptoms associated with the presence varicose veins. These results warrant further exploration in a longer, randomized and placebo-controlled study.Trial registrationClinicaltrial.gov: NCT03653793
Ashraf Nusairat - One of the best experts on this subject based on the ideXlab platform.
-
wimax ofdma burst scheduling algorithm to maximize Scheduled Data
IEEE Transactions on Mobile Computing, 2012Co-Authors: Ashraf NusairatAbstract:OFDMA resource allocation algorithms manage the distribution and assignment of shared OFDMA resources among the users serviced by the basestation. The OFDMA resource allocation algorithms determine which users to schedule, how to allocate subcarriers to them, and how to determine the appropriate power levels for each user on each subcarrier. In WiMAX, the downlink (DL) TDD OFDMA subframe structure is a rectangular area of N subchannels \times K time slots. Users are assigned rectangular bursts in the downlink subframe. The size of burst, in terms of number of subchannels and number of time slots, varies based on the user's channel quality and Data to be transmitted for the assigned user. In this paper, we study the problem of assigning users to bursts in WiMAX TDD OFDMA system with the objective of maximizing downlink system throughput for the Partially Used subcarrier (PUSC) subchannalization permutation mode. Our main contributions in this paper are: 1) we propose different methods to assign bursts to users, 2) we prove that our Best Channel burst assignment method achieves throughput within a constant factor of the optimal, 3) through extensive simulations with real system parameters, we study the performance of the Best Channel burst assignment method. To the best of our knowledge, we are the first to study the problem of DL Burst Assignment in the downlink OFDMA subframe for PUSC subchannalization permutation mode taking user's channel quality into consideration in the assignment process.
-
Wimax/ofdma burst scheduling algorithm to maximize Scheduled Data
2011Co-Authors: Ashraf Nusairat, Senior MemberAbstract:Abstract—OFDMA resource allocation algorithms manage the distribution and assignment of shared OFDMA resources among the users serviced by the basestation. The OFDMA resource allocation algorithms determine which users to schedule, how to allocate subcarriers to them, and how to determine the appropriate power levels for each user on each subcarrier. In WiMAX, the downlink (DL) TDD OFDMA subframe structure is a rectangular area of N subchannels K time slots. Users are assigned rectangular bursts in the downlink subframe. The size of burst, in terms of number of subchannels and number of time slots, varies based on the user’s channel quality and Data to be transmitted for the assigned user. In this paper, we study the problem of assigning users to bursts in WiMAX TDD OFDMA system with the objective of maximizing downlink system throughput for the Partially Used subcarrier (PUSC) subchannalization permutation mode. Our main contributions in this paper are: 1) we propose different methods to assign bursts to users, 2) we prove that our Best Channel burst assignment method achieves throughput within a constant factor of the optimal, 3) through extensive simulations with real system parameters, we study the performance of the Best Channel burst assignment method. To the best of our knowledge, we are the first to study the problem of DL Burst Assignment in the downlink OFDMA subframe for PUSC subchannalization permutation mode taking user’s channel quality into consideration in the assignment process. Index Terms—WiMAX, OFDMA, wireless scheduling, burst scheduling, throughput maximization Ç
